US biopharmaceutical company Gilead plans Hoofddorp production unitPublished on 12-06-2018
California-based biopharmaceuticals group Gilead plans to build a production unit in Hoofddorp near Schiphol Airport. The facility will produce cell therapies used against cancer and will serve all of Europe from 2022, it will employ at least 300 people.
Gilead was established 30 years ago and last year the company booked revenues of more than $ 28 billion. Its primary therapeutic focus continues to be in antiviral medicines and the company approval of cell therapy treatments in Europe later this year.
Gilead said it is essential to have a European production unit because treatments are tailor made for individual patients and speed of delivery is crucial.